GDXJ vs XBI
VanEck Junior Gold Miners ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.52% for GDXJ.
- • GDXJ pays a higher dividend yield (2.27%).
Side-by-side metrics
| Metric | GDXJ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.52% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.27% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $8.72B | $8.30B |
YTD return | 7.88% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.86 | 1.09 |
P/E ratio | 17.66 | — |
Last price | $122.42 | $133.66 |
Inception | — | — |
Issuer | VanEck | State Street |
GDXJ top holdings
| AGI.TO | Alamos Gold Inc Class A | 6.81% |
| EQX.TO | Equinox Gold Corp Ordinary Shares Class A | 6.40% |
| CDE | Coeur Mining Inc | 6.39% |
| EVN.AX | Evolution Mining Ltd | 6.13% |
| EDV.L | Endeavour Mining PLC | 5.87% |
| PE&OLES.MX | Industrias Penoles SAB de CV | 2.85% |
| AG.TO | First Majestic Silver Corp | 2.58% |
| HL | Hecla Mining Co | 2.20% |
| IMG.TO | Iamgold Corp | 2.14% |
| LUG.TO | Lundin Gold Inc | 2.03% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About GDXJ
GDXJ (VanEck Junior Gold Miners ETF) is Small and mid-cap gold and silver mining companies. Managed by VanEck, the fund carries $8.7B in assets under management, an expense ratio of 0.52%, a dividend yield of 2.27%. Its largest holding is Alamos Gold Inc Class A (AGI.TO), which represents 6.8% of the portfolio. Basic Materials is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.